SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (21013)5/25/1998 1:10:00 PM
From: WTDEC  Read Replies (2) | Respond to of 32384
 
Henry, since both Herceptin and DAB389-EGF are designed to kill cells over expressing EGF (including breast tumors), the differences between them, it seems to me, would be in the method of kill and the method of getting to the errant cells (in my obvious layman language).

Do you have any opinion on the differences, which seems better, etc.? Looks like Herceptin will get to market first.

Regards,

Walter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News